Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study

Table 5 Overview of adverse events–safety population

	Events (n = 55)	Patients (n = 98)
All AEs	55	18 (18.4%)
Severe AEs	10 (18.2%)	5 (5.1%)
AEs related to study drug	17 (30.9%)	12 (12.2%)
Mild	5 (29.4%)	4 (4.1%)
Moderate	6 (35.3%)	6 (6.1%)
Severe	4 (23.5%)	2 (2.0%)
Not provided	2 (11.8%)	2 (2.0%)
Serious AEs	27 (49.1%)	7 (7.1%)
Number of patients with AEs
Resulting in hospitalization		6 (6.1%)
Resulting in study drug discontinuation		15 (15.3%)
Malignancy in patients ≤ 30 yr	0	0
Death	0	0

Percentages of patients were calculated based on the total number of patients. Percentages of events were based on the total number of events.

AE: Adverse event.